Cerebrospinal fluid seed aggregation assay and Alzheimer biomarkers in a Dementia with Lewy Body cohort

Determination of DLB status using CSF SAA test in this clinical DLB cohort revealed high (77%) positivity. Repeated CSF evaluations revealed that SAA measurements, whether negative or positive, remained consistent over 1-2 years. For the few individuals who were SAA negative, there was no evidence of increased Alzheimer pathology by CSF biomarkers, although the one SAA negative case that came to autopsy was also negative for Lewy body pathology.